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Abstract
Background: Hepatitis C (HCV) prevalence is most common amongst injecting drug users where
up to 98% of the population can be infected despite a low prevalence of HIV. This review considers
the evidence for the effectiveness of primary prevention interventions to reduce incidence or
prevalence of hepatitis C.
Methods:  Systematic review of the major electronic medical databases: Medline, EMBASE,
PsycINFO, CINAHL and the Cochrane Library (Evidence Based Health). Either intervention or
observational studies were included if they described an intervention targeting injecting drug using
populations with the outcome to reduce either the prevalence or incidence of hepatitis C infection.
Results: 18 papers were included in the final review from 1007 abstracts. Needle exchange
programmes reduce the prevalence of HCV though prevalence remains high. Similarly the
effectiveness of methadone maintenance treatment is only marginally effective at reducing HCV
incidence. There is limited evidence evaluating either the effectiveness of behavioural interventions,
bleach disinfectants, or drug consumption rooms.
Conclusion: Primary prevention interventions have led to a reduction in HIV incidence, have been
less effective at reducing HCV incidence. Global prevalence of HCV remains disturbingly high in
injecting drug users. A robust response to the global health problem of HCV will require provision
of new interventions. Behavioural interventions; distribution of bleach disinfectant; other injecting
paraphernalia alongside sterile needle distribution; and evaluation of drug consumption rooms
merit further expansion internationally and research activity to contribute to the emerging
evidence base. Whilst the prevalence of HCV remains high, nevertheless many current
interventions aimed at primary HCV prevention have been shown to be cost-effective due to their
significant positive impact upon prevalence of HIV.
Background
Hepatitis C (HCV) is a blood borne virus (BBV) with
potentially devastating hepatic complications [1]. While
approximately 20% of acutely infected people will clear
the virus and recover, up to 80% will develop chronic hep-
atitis C [2]. The World Health Organization (WHO) esti-
mates that 3% of the world's population is infected [3]
and hepatitis C has been declared a global public health
problem. Nucleotide sequence analysis has highlighted
six HCV genotypes which can be further categorized
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according to subtypes [4]. Differing genotypes are distrib-
uted differently by geographical region and route of infec-
tion, and have differing sensitivity to anti-viral treatment
regimes [5]. In Japan, North America and Western Europe
the majority of genotypes are numbers 1, 2 and 3, whereas
genotype 4 is more prevalent in the Middle East and in
North and Central Africa. Types 5 and 6 have been identi-
fied in South Africa and South East Asia, respectively [6].
While a number of risk factors have been identified, intra-
venous drug use is the major mode of HCV transmission
[2,7]. Other transmission risk factors include receiving a
blood transfusion or blood products before the availabil-
ity of heat-treated factors in the mid 1980s in the UK,
using non-sterilized equipment in dental, surgical, skin
piercing and tattooing procedures, clinical injuries from
dental or surgical procedures or needle stick injuries [8-
10], vertical transmission (materno-fetal) and sexual
spread [1].
A systematic review of HCV prevalence or incidence data
for injecting drug users (IDUs) in European Union (EU)
countries identified 98 studies [11]. Prevalence ranged
from 30% to 95% among males, 48% to 94% among
females and 33% to 98% among those of unspecified gen-
der. This wide range in prevalence is confirmed by the
European Monitoring Centre for Drugs and Drug Addic-
tion (EMCDDA) [12,13], and concurs with a systematic
review of seroprevalence of HCV markers among intrave-
nous drug users (IVDUs) in western Europe [14]. Associa-
tions between increasing age, increasing duration of IDU
or imprisonment and anti-HCV seropositivity were
described. However, caution should be exercised in con-
sidering solely the results of prevalence studies when
exploring risk factors for anti-HCV seroconversion. In
addition to describing associations and not causal rela-
tionships, different countries differ in the data sources
used to collect prevalence data. Additionally, in some sit-
uations, biochemical tests may underestimate prevalence.
There are also warnings about comparing prevalence data
with previous versions to follow changes over time, as
inclusion of sources may vary according to data availabil-
ity [13]. However prevalence data is not solely a marker of
primary prevention, which is the process of preventing
disease transmission. It is also a marker of secondary pre-
vention, the process of eradicating the disease in those
with established infection.
Therefore, to further understand the epidemiology of
HCV so as to explore the effectiveness of primary preven-
tion interventions, the international studies of anti-HCV
incidence must be considered. The range of reported inci-
dence of anti-HCV seroconversion is from 11 to 29 per
100 person-years [10,15-19]. Independent risk factors for
HCV seroconversion include a history of imprisonment, a
history of needle or other paraphernalia sharing and poly-
drug use, in particular using heroin and cocaine together
[10,15,16,19]. While some incidence studies report
younger age being an independent risk factor, others
report older age [19]. However, the latter is strongly con-
founded with the duration of the injecting career and this
is arguably a greater independent risk factor than age for
anti-HCV seroconversion. The difficulty of adequately
controlling for confounders of age was highlighted in a
review of prevalence studies which described a linear pos-
itive relationship between increasing age and prevalence
of anti-HCV-RNA in anti-HCV positive injecting popula-
tions [14]. The commentators offered possible explana-
tions that HCV infection is more likely to resolve at a
younger age, the natural history of the disease is character-
ized by frequent initial long periods of undetectable viral
load levels, and age increases the risk of continuing expo-
sure and re-infection. Similarly, there is no concordance
between incidence studies as to whether gender is an inde-
pendent risk factor, as some report a higher incidence in
males [16], and others in females [17]. It is therefore pos-
sible that gender is confounded with other independent
variables.
Methods
Search strategy
A full copy of the search strategy is available from the
authors upon request. Briefly the following databases
were searched: Medline, EMBASE (1980 to 2003 week
23), PsycINFO (1872 to April week 2 2003), CINAHL
(1982 to March week 4 2003) and the Cochrane Library
(Evidence Based Health) using search terms related to
"drugs" "drug use" and "hepatitis C". Additionally, the
index pages of the last five years publications of selected
relevant, high-impact journals were searched by hand.
The internet was also searched using key terms relating to
hepatitis C and injecting drug use and reference lists of rel-
evant papers were scanned. The search was not limited
solely to publications in the English language (though not
all identified papers were translated as many once
retrieved were opinion pieces or descriptive studies). Pos-
sibility of publication bias was reduced by speaking with
experts regarding relevant unpublished grey literature.
Study selection
The protocol for selection criteria was informed by
acknowledged historical political difficulties in obtaining
research funding for experimental research in the field of
reducing harm amongst drug users [20]. Either interven-
tion or observational studies were included in the review
if they described a primary prevention intervention target-
ing injecting drug using populations with the outcome to
reduce either the prevalence or incidence of hepatitis C
infection. Abstracts identified were reviewed by two
researchers independently against agreed inclusion andHarm Reduction Journal 2006, 3:27 http://www.harmreductionjournal.com/content/3/1/27
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exclusion criteria. Any discrepancy was resolved by discus-
sion.
Descriptive studies, qualitative studies, editorials and
opinion pieces were excluded from the review. Due to
space constraints interventions targeting the general pop-
ulation (e.g. screening of blood products or prevention of
vertical transmission) whilst alluded to in the original
synthesis [21] are not included in this review. Quality of
the studies was based on a checklist of criteria to include:
clear case definition of anti-HCV positivity (type of bio-
chemical test used); location (city, country, number and
type of treatment settings); years of recruitment (and total
duration of recruitment); number of participants (and
breakdown by age, gender, ethnicity, sexual orientation,
type of drug used, mean length of illicit drug use, employ-
ment status, housing status); percentage of those identi-
fied recruited into study; percentage follow-up of
participants.
The checklist devised specifically for randomised control-
led trials covered: a clear description of the randomisation
process and whether open, single blind, or double blind;
clear description of the concealment process; steps taken
to avoid contamination; steps taken to ensure independ-
ence of data analysis; use of intention-to-treat analysis.
The checklist for quasi-experimental or case-control stud-
ies covered: whether baseline data were reported; poten-
tial for selection bias described and accounted for in the
analysis; potential for confounders described and
accounted for either by multivariate analysis or stratifica-
tion; steps taken to ensure independence of data analysis.
Finally, the checklist devised specifically for observational
cohort studies covered: whether probabilistic sampling
methods were used to select participants; use of a control
group; potential confounders described with an attempt
made to quantify the effect either by multivariate statisti-
cal analysis or stratification; potential for loss to follow-up
bias described and accounted for in the analysis (as a min-
imum description of any difference in baseline demo-
graphics between those followed up and those lost to
follow-up).
Results
The review process identified 1007 abstracts. 155 full text
papers were retrieved of which 18 met the inclusion crite-
ria (see figure 1). The included papers were categorised
according to type of intervention. 11 papers were catego-
rised according to the theme of "needle exchange", 3
according to the theme "opiate replacement therapy", 1
according to the intervention of "bleach disinfectant", and
3 according to "expanded harm reduction" (where the
harm reduction interventions of needle exchange, metha-
done maintenance, safer injecting advice or the effect of
counsellors/therapists was not evaluated independently)
and none to drug consumption rooms. No intervention
studies were identified and of the observational studies
identified, the intervention of needle exchange was the
most evaluated. It also appeared to be the intervention
that had been most contentious when first introduced.
For these reasons a précis of the historical debates as they
related to the topic of HIV transmission and also cost
effectiveness evaluations are reported below. This is in
addition to the studies observing their effectiveness as a
primary prevention intervention. No intervention studies
assessing the impact of harm reduction interventions at
reducing hepatitis C in prisons were identified in the
search.
As no intervention studies were identified it was not
appropriate to conduct a meta-analysis. Rather the results
are reported in the form of a narrative systematic review.
Such a narrative format has been described as appropriate
in reporting the results of observational studies identified
through a process of systematic review [22]. The terms
"antibodies to HCV", "HCV antibodies", "anti-HCV posi-
tive" and "anti-HCV seroconversion" are common terms
used in the literature to describe a positive antibody
response to HCV infection. However, not all those who
Papers Identified in the Systematic Review Figure 1
Papers Identified in the Systematic Review.
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are anti-HCV positive are viremic. Active viral replication
as evidenced by the presence of serum viral RNA means
that the person is a carrier of HCV. Such a state is referred
to as anti-HCV-RNA positive. Successive generations of
tests have led to an improved sensitivity and specificity of
testing [23]. Currently anti-HCV seropositivity is assessed
by third-generation enzyme-linked immunosorbent assay
(ELISA) test. Unless specifically stated otherwise, where
anti-HCV seropositivity is reported, a third-generation
ELISA test was used for diagnosis.
Can needle exchange programmes reduce prevalence of 
HCV?
The evaluation of the effectiveness of needle exchange
programmes (NEPs) at reducing the risk of blood-borne
viruses has been limited for several reasons. These include
political legitimacy (which has been variable between dif-
ferent countries) as historically NEPs have been a conten-
tious subject; difficulty quantifying the direct effect of
NEPs as often there is an interaction with other factors
causing a reduction (e.g. provision of bleach or counsel-
ling); or the effect of secondary exchange [20]. Evaluation
has also been hampered as it is deemed unethical to eval-
uate using randomised control trial methodology. The
limitations of observational research have been the diffi-
culty in mitigating against selection bias of the most high
risk users into NEPs. This limitation has on occasions
fuelled the debate concerning the possibility of needle
exchanges actually causing an increase in blood borne
virus transmission.
An example of this was the contentious debate following
the outbreak of HIV in Vancouver, Canada in 1994 [24].
The rapid rise in HIV prevalence was preceded by the
introduction of an NEP in 1989. Prior to the outbreak
Vancouver had a low HIV prevalence rate and it was
assumed that this was due to the effectiveness of the NEP.
The outbreak led to several observational studies which
sought to explore a possible causal link between the NEP
and the HIV outbreak. An initial outbreak investigation in
1995 found an independent association between needle
sharing, and social determinants (such as unstable hous-
ing) and HIV seroconversion [25]. This led to a prospec-
tive cohort study of 1006 IDUs. Whilst the limited
number of HIV seroconverters precluded a formal early
statistical analysis, multivariate analysis of baseline data
documented an independent association between HIV-
positive serostatus and frequent (>once per week) NEP
attendance. NEPs were thus criticised for promoting
unsafe injecting drug use behaviour (or at the very least
condoning injecting drug use). It was postulated that the
NEP could act as a focus for forming social networks con-
ducive to the initiation into unsafe injecting practice.
Political ramifications were highlighted in the USA where
the results were interpreted as evidence of a causal link
between NEP use and HIV seroconversion leading to a
continued ban on the use of federal funds to support
NEPs [26-28]. However longitudinal analysis of HIV inci-
dence amongst a sample of 694 subjects was reported in
1999 [28]. Univariate analysis of the data could have led
one to postulate a causal link between the NEP and HIV
seroconversion as cumulative incidence was significantly
elevated in frequent attenders at the NEP. However fre-
quent attenders were younger and more likely to report:
unstable housing and hotel living; the downtown eastside
part of the city as their primary injecting site; frequent
cocaine injection; sex trade involvement; injecting in
"shooting galleries"; or incarceration within the previous
six months. Multivariate analysis to account for these con-
founders demonstrated that there was no independent
causal link between NEP attendance and HIV seroconver-
sion.
Within such a contentious international context, a series
of large observational studies conducted in Scotland in
the mid-1990s compared prevalence of anti-HCV for the
periods before during and after introduction of NEPs. The
supporting data and full results are presented in a sum-
mary of relevant studies [see Additional File 1] [29-32].
Results showed a statistically significant reduction in anti-
HCV prevalence in the early 1990s (shortly after the intro-
duction of NEPs). Reduction was greatest in the under
25s. However, evaluation in the late 1990s showed that
the declining trend in overall prevalence did not continue.
There was only a reduction for those aged over 25. The
authors concluded that the incidence of HCV decreased
during the 1990s, but remained high. Such findings are
confirmed by an Australian prevalence study showing a
reduction in anti-HCV incidence from 63% in 1995 to
51% in 1996 to 50% in 1997 [33], a Swedish cohort study
[34] and a Swiss longitudinal and cross-sectional survey
(including serological testing) [35,36]. The latter reported
a reduction in anti-HCV prevalence after 1991 (when
both needles and syringes were available) compared to
1988–1990 (when needles but not syringes were availa-
ble) compared to before needle and syringe exchange in
1987. Two American studies failed to find a causal link
between NEPs and HCV incidence. One case control study
showed non-use of NEPs to be associated with a seven-
fold greater risk of anti-HCV seroconversion [37]. The
other, a prospective cohort study, showed a statistically
non-significant increase in HCV with NEP use [38]. One
Canadian study had insufficient power to determine a
reducing trend in HCV incidence over the study period
[17].
Whilst not studying the outcome of anti-HCV incidence,
two large observational studies conducted in the United
States demonstrate that the introduction of NEPs leads to
a self-reported reduction in sharing when associated withHarm Reduction Journal 2006, 3:27 http://www.harmreductionjournal.com/content/3/1/27
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an increase in distribution. Such increase in distribution
does not lead to an increase in injecting drug use or a
switch from non-injecting to injecting [39,40].
Cost-effectiveness of needle exchange programmes
One of the most comprehensive reports on the cost effec-
tiveness of NEPs was published by the Commonwealth
Department of Health and Ageing of Australia in 2003
[41]. Employing ecological study methodology, changes
in HCV and HIV prevalence were compared in cities that
had NEPs with those that did not. There were 190 calen-
dar years of HCV seroprevalence data from 101 cities. Pre-
NEP introduction HCV prevalence rates of 75% or 50%
corresponded to a 1.5% or 2% decline in HCV prevalence
per annum. The cost-effectiveness of NEPs is optimized by
the combined effect of reduction in HIV and reduction in
HCV. The financial return on government investment in
NEPs regarding the impact on HIV and HCV combined
was calculated at a lifetime saving to costs of treatment of
$3 653AUD million in treatment costs. A total gain of 170
279 Quality Adjusted Life Years (QALYs) were also calcu-
lated due to avoiding HCV and HIV. These findings con-
curred with American research that conducted a random
mixing statistical model using sensitivity analysis to quan-
tify the cost-effectiveness of NEPs in reducing the inci-
dence of HCV [42], concluding that NEPs need to be
integrated as part of broader interventions to reduce the
population prevalence of HCV and thus maximize cost-
effectiveness.
Effect of opiate replacement therapy on HCV 
seroconversion
While buprenorphine and methadone are the two most
common agents used for opiate replacement therapy, no
studies evaluating the effectiveness of buprenorphine
could be located. As regards methadone maintenance
therapy, whilst it has been successful in reducing the inci-
dence of HIV, the evidence for its effectiveness in reducing
HCV incidence is less convincing [see Additional File 1]
[18,43-47]. Indeed, an Italian nested case control study
evaluated the impact of MMT on 746 injecting heroin
users [45]. 263 IDUs were HCV negative at baseline and
106 (40.3%) underwent re-testing. Total follow up time
was 73.4 person years, during which time 21 individuals
seroconverted, an incidence rate of 28.6 per 100 person
years (95% CI 17.8–43.4). The adjusted odds ratio for
"lack of methadone treatment" (in the six months prior to
testing) was of borderline significance (2.9, 95% CI 0.9–
9.7).
Such equivocal conclusions were also the findings of a
prospective cohort study assessing causal associations
between retention in methadone treatment and HCV in
716 IDUs in Seattle, USA [46]. Participants were catego-
rised into either left treatment, disrupted treatment or
continued treatment. There was a marked difference in
reducing or stopping injection between the treatment sta-
tus groups and the primary outcome variables measured
the incidence of HCV or HBV over the study period. Mul-
tivariate analysis showed a non-statistically significant
lower incidence of HCV seroconversion in those who
remained in treatment (AOR = 0.4, 95% CI 0–4.2) com-
pared to those who had left (AOR = 1.0). Cessation of
injecting at follow up was statistically significantly associ-
ated with continuing treatment (AOR = 0.1, 95% CI 0.1–
0.2). This study is confirmed by the findings a Dutch pro-
spective cohort study [47]. It found no statistically signif-
icant reduction in HCV incidence (chi-squared (χ2) test
for trend P = 0.79) despite the provision of methadone
programs, NEPs, free condom distribution and an infor-
mation campaign. However the limitations of the study
were that none of these variables where controlled for in
the analysis.
Three separate observational studies evaluating the inci-
dence of anti-HCV seroconversion amongst cohorts tak-
ing MMT did not demonstrate any statistically significant
difference in incidence between those taking MMT and
those not [18,43,44]. However, these studies only used
univariate analysis. Additionally, only one study [44]
reported the mean methadone doses that may affect the
reduction in anti-HCV incidence. This may be important
as some commentators have argued that under-dosing
would reduce the effectiveness of MMT at reducing unsafe
injecting behaviour [48,49]. Additionally, it has been
argued that while users are likely to contract hepatitis C
early in their injecting, they do not present to MMT serv-
ices until later years, when they are more likely to have
contracted HCV [49].
Effect of behavioural programmes on HCV seroconversion
Behavioural interventions work within a framework of
psychological theory. Such interventions can be delivered
at the individual or group level. They seek to increase
readiness to change by building trust and reducing resist-
ance [50]. They seek to increase users self efficacy and their
perceived discrepancy between their actual and ideal
behaviour [51]. However, we were unable to identify any
intervention studies evaluating the impact of behavioural
programmes at reducing the incidence or prevalence of
anti-HCV.
Three observational studies alluded to the effect of harm
reduction programmes which included the effect of "out-
reach workers", "counsellors", or "advice" [47,52,53].
However none of these studies described the framework
of psychological theory. Also none of the studies evalu-
ated the interventions separately from other interventions
such as NEPs, condom distribution or opiate mainte-
nance therapy. Two studies [47,52] demonstrated a statis-Harm Reduction Journal 2006, 3:27 http://www.harmreductionjournal.com/content/3/1/27
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tically significant reduction in HCV due to the overall
programme. The other study noted a reduction in the
prevalence of HIV after the introduction of preventive
measures (condoms and safer injecting advice). Therefore
it is not possible to draw definitive conclusions from these
studies. It is plausible that "advice" or more structured
behavioural interventions delivered alongside other harm
reduction interventions does reduce the incidence of HCV
but there is a need for further research to evaluate the
effect of such interventions.
Does bleach distribution reduce the risk of HCV?
Some commentators argue that training drug users to
clean syringes effectively gives false assurance, reduces the
validity of health advice to never share another person's
injecting equipment and reduces the health policy imper-
ative to ensure that sufficient needles are distributed [54].
However, recent qualitative research has shown that nee-
dle sharing is not a fixed behaviour, but is more likely
when a user is withdrawing and has obtained drugs but
does not have access to clean injecting equipment [55].
There appears to be limited evidence to inform best prac-
tice. One under-powered case control study nested within
a prospective cohort study of 390 IDUs from five Ameri-
can cities reported a statistically non-significant reduction
trend of lower anti-HCV seroconversion for those who
used bleach all the time, compared to those who used it
some of the time, to those who did not use it at all ()[56].
Drug consumption rooms and hepatitis C
Drug consumption rooms (also known as supervised
injecting rooms or medically supervised injecting centres)
are legally sanctioned and supervised facilities designed to
reduce the health and public order problems associated
with illegal injection drug use [57]. Their purpose is to
enable the consumption of drugs under hygienic, low-risk
conditions. Trained health staff, while not physically
helping users to inject illicit drugs, supervise injecting in
order to avoid high-risk drug taking and to ensure hygi-
enic practices. Part of their intended benefit is to reduce
drug-related harm associated with transmission of blood-
borne virus infections. Internationally, there has been a
recent increase in the number countries operating drug
consumption rooms though at the time of writing the UK
does not have a legal framework sanctioning their provi-
sion. We were only able to find one evaluation of a drug
consumption room that specifically studied anti-HCV
conversion as an outcome. The evaluation was a time
series analysis from an early evaluation of a drug con-
sumption room in Australia. Whilst statistical analysis was
reported in the paper, for the outcome of anti-HCV con-
version descriptive data only was presented. Such data
found no change in the incidence of notifications of hep-
atitis C infections among local users during the 18-month
trial period, despite an increase in notifications from
neighbouring areas [58]. The report acknowledges, how-
ever, that the low population prevalence of the infections
in Australia may make it difficult to detect any statistically
significant changes. A more recent report on drug con-
sumption rooms concurred that few data are available
regarding the impact of such centres on the incidence of
drug-related infectious diseases [59]. It is plausible that
these rooms can contribute to a reduced incidence of HCV
given that numerous surveys show that high-risk users use
such centres and report significant reductions in BBV risk
behaviour [60-64].
Discussion and conclusion
Reducing the incidence of HCV continues to present a
considerable challenge. Recent UK based research con-
ducted amongst injecting drug users documented an inci-
dence rate of 41.8 per 100 person years for HCV and 3.4
per 100 person years for HIV [65]. Therefore in the
absence of an immediate prospect of a vaccine against
HCV [66], over-reliance should not be placed on any one
harm and risk reduction intervention. Provision of clean
needles and syringes are interventions for which there is
an evidence base. Providing optimal dose opiate substitu-
tion therapy; drug consumption rooms as a hygienic place
for those who engage in public injecting; behavioural
interventions; and bleach and injecting paraphernalia dis-
tribution alongside needle and syringe distribution are all
interventions that merit further expansion internationally
supported by pragmatic research activity to contribute to
the emerging evidence base. There is some evidence from
the USA that sharing of "cookers" (usually the spoon or
metal container used to prepare and heat drugs) presents
a greater risk to the spread of HCV than the sharing of
either cotton filters or water [67] though our review did
not identify any studies evaluating the effects of parapher-
nalia distribution at reducing the incidence or prevalence
of HCV.
One limitation of this review is that the comprehensive
search was completed in 2002 to allow for submission
and peer review by the WHO Health Evidence Network.
Since that time some new literature has emerged in rela-
tion to prison based NEPs. An international review of
prison based syringe exchange programmes published in
2003 reported that in small prisons with a high prevalence
of injecting drug use, the introduction of NEPs led to a
decrease in needle and syringe sharing over time whilst
the prevalence of drug use decreased or remained stable.
Whilst in one centre there were no new cases of HCV
reported following the introduction of the NEP, there is a
need for more epidemiological work quantifying the
impact of NEPs in the prison setting upon HCV transmis-
sion.Harm Reduction Journal 2006, 3:27 http://www.harmreductionjournal.com/content/3/1/27
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Such work will require political will. Whilst internation-
ally there has been minimal funding for pragmatic inter-
vention trials in this field due to a lack of political will, the
recently published UK Department of Health Hepatitis C
Action Plan provides a window of opportunity to focus
political, research and clinical resources upon the com-
mon goal of reducing the incidence of HCV [68,69]. How-
ever to inform resource allocation, policy makers will
require improved data sources to monitor the societal
health burden of the chronic sequelae of HCV infection.
This need for improved data sources of HCV incidence
and prevalence has been highlighted by some commenta-
tors [70]. Figure 2 highlights possible data sources in
which they have proposed possible data sources for mon-
itoring HCV incidence and prevalence amongst both
injecting drug using and generic populations [70]. Moni-
toring trends amongst generic populations would have
relevance to IDUs as it would provide ongoing data
regarding the proportion of disease burden attributable to
injecting drug use.
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Proposed data sources for monitoring HCV incidence and  prevalence Figure 2
Proposed data sources for monitoring HCV incidence and 
prevalence.
Registration of confirmed hepatitis C infections and information on HCV-test uptake:
• a registry of confirmed HCV infections including the individual’s first name initial, a 
soundex of the surname, date of birth, gender, postcode, district of residence, health board 
of residence, risk factor, source of referral and previous HCV test history. (If injecting 
drug use is the risk factor, then “year of starting to inject” should be recorded since this 
marks the likely start of an individual’s seroconversion interval); 
• surveys of HCV test-uptake by injectors and others, which are currently unavailable in the 
United Kingdom and other countries; 
• documentation of pregnancy and its outcome in HCV-infected women, including 
paediatric surveillance for HCV infections; 
• anonymous testing for HCV antibodies in blood or saliva for at risk groups (including 
new blood-donors, pregnant women, patients awaiting kidney transplantation, non-
injector prisoners, health care workers, or non-injector heterosexuals attending 
genitourinary medicine clinics, injectors in the community undergoing testing at drug 
treatment centres, or injectors undergoing testing in the prison environment); 
• historical data on HCV prevalence in injectors;
• HCV incidence studies in injectors;
• uptake of harm-reduction measures by injectors (frequency of needle sharing and 
methadone substitution). 
Data sources for monitoring the late consequences of hepatitis C carriage, its investigation and 
treatment:
• linkage surveillance (for example by master index to identify deaths, hospitalization or 
cancer registrations among confirmed HCV infected people); 
• surveys of HCV status among patients attending Hepatology services (including those 
who undergo liver biopsy, are newly diagnosed with cirrhosis, or are newly diagnosed 
with liver cancer); 
• surveys of liver biopsy rate in HCV-infected injectors and others;
• uptake and outcome of anti-viral therapy in the treatment of HCV carriers;
• cohort studies of HCV progression;
• sample surveys of genotype in HCV-infected persons;
• acute hepatitis B infections and uptake of hepatitis B immunization by injectors;
• liver transplantation in HCV-infected patients;
• HCV status and other risk factors in deaths from cirrhosis or liver cancer (to determine
whether they are HCV-related or injector-related). 
Potential data sources for quantifying the scale of the underlying injector epidemic: 
• drug misuse databases analysed using capture-recapture methods to assess the number of 
injectors
• drug-related deaths by region to assess number of injectors
• number of HIV-infected injectors
• HIV progression in injectors
• overdose and other causes of death in injectors
• expert opinion on injector incidence combined with survey information on age-
distribution at initiation and the duration of injecting careers
• injector incidence historically inferred from HCV-infected blood donors
• age distribution of current injectors, and at initiation (to validate the assumptions behind 
statistical modelling of HCV population prevalence data made from local surveys)
• mortality of former injectors
• general population (or other) survey ratios of surviving ever-injectors to injectors in (for 
example) the last five years, last year, and currently.Harm Reduction Journal 2006, 3:27 http://www.harmreductionjournal.com/content/3/1/27
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